article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Anthrax is a rare, yet severe disease caused by the bacterium B. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. These antibodies play a crucial role in providing protection by effectively neutralizing the cytotoxic lethal toxin and edema toxin of B. Overall, 66.3

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.

Sales 98
article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

Most antibody drugs and vaccines have been developed to target parts of the spike protein. Drug Approvals. So far, the FDA has approved a handful of drugs for the treatment of COVID-19. These include remdesivir, baricitinib, dexamethasone and three antibody drugs.